Clearside Biomedical
Biotechnology Research • 
Alpharetta, Georgia, United States • 21-50 Employees
Company overview
| Headquarters | 900 North Point Parkway, Suite 200, Alpharetta, GA 30005, US |
| Phone number | +16782703631 |
| Website | |
| NAICS | 541714 |
| SIC | 384 |
| Keywords | Ophthalmology, Retinal Disease, Uveitis, Wet-Amd, Diabetic Macular Edema, Suprachoroidal Space |
| Founded | 2012 |
| Employees | 21-50 |
| Socials |
Key Contacts at Clearside Biomedical
Thai Nguyen
Sr. Director, Cmc
Chen-Rei Wan
Sr. Director Of Engineering
Andrew Alexander
Senior Director, It
Barry Kapik
Senior Director, Biostatistics
Joe Deen
Senior Director Medical Affairs
Janet Stanish
Sr. Director, Quality Assurance And Compliance
Nathan Fisher
Director Medical Affairs
George Lasezkay
President And Chief Executive Officer
Keleigh Mahn
Sr. Director Of Quality
Lori Dillard Hall
Senior Director, Quality Engineering And Supplier Quality
Clearside Biomedical Email Formats
Clearside Biomedical uses 3 email formats. The most common is {first initial}.{last name} (e.g., j.doe@clearsidebio.com), used 79.4% of the time.
| Format | Example | Percentage |
|---|---|---|
{first initial}.{last name} | j.doe@clearsidebio.com | 85.3% |
{first name}.{last name} | john.doe@clearsidebio.com | 14.7% |
About Clearside Biomedical
Clearside Biomedical, Inc. is a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®). Clearside’s SCS injection platform, utilizing the Company’s proprietary SCS Microinjector®, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. Clearside is developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector and strategically partners its SCS injection platform with companies utilizing other ophthalmic therapeutic innovations. Clearside’s first product, XIPERE™ (triamcinolone acetonide injectable suspension) for suprachoroidal use, was approved by the U.S. Food and Drug Administration in October 2021.
Clearside Biomedical revenue & valuation
| Annual revenue | $4,166,000 |
| Revenue per employee | $116,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $13,400,000 |
| Total funding | $80,000,000 |
Employees by Management Level
Total employees: 21-50
Seniority
Employees
Employees by Department
Clearside Biomedical has 16 employees across 7 departments.
Departments
Number of employees
Funding Data
Explore Clearside Biomedical's funding history, including investment rounds, total capital raised, and key backers.
Clearside Biomedical Tech Stack
Discover the technologies and tools that power Clearside Biomedical's digital infrastructure, from frameworks to analytics platforms.
Video players
JavaScript libraries
JavaScript libraries
JavaScript libraries
Font scripts
JavaScript libraries
Programming languages
Blogs
Analytics
Video players
UI frameworks
Belgium
United Kingdom
Sweden
Denmark
Czechia
Frequently asked questions
4.8
40,000 users
